Streptozotocin-Based Chemotherapy is Still Alive in Patients with Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival

#1009

Introduction: Chemotherapy with Streptozotocin (STZ) and 5-FU or Doxorubicin (Doc) represents a standard of care for patients with well-differentiated metastatic neuroendocrine neoplasms, especially for the pancreas (PNENs). However, data to identify predictive and prognostic markers are limited.

Aim(s): Evaluation of clinicopathological characteristics and possible predictive and prognostic markers of patients receiving this combination.

Materials and methods: We retrospectively analyzed 77 patients who were treated at the University Hospital Marburg between 1995 and 2013. The median overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier and Cox regression methods, respectively.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Krug S, Boch M, Rinke A, Müller D, König A,

Keywords: streptozotocin, NEN, 5-fluorouracil, Doc,

To read the full abstract, please log into your ENETS Member account.